gloveharicut
CIMB: More smoke than fire in GLOVE
gloveharicut
Publish date: Wed, 19 Aug 2020, 09:24 PM
{{{PM me to join GLOVE Private Discussion Room}}}
I invite you to read my blog and make a smart GLOVE decision.
https://klse.i3investor.com/blogs/gloveharicut/blidx.jsp
I am reproducing the CIMB report to my blog.
Related Stocks
| Chart | Stock Name | Last | Change | Volume |
|---|
Market Buzz
2024-12-27
HARTA2024-12-27
HARTA2024-12-27
SUPERMX2024-12-27
TOPGLOV2024-12-26
HARTA2024-12-26
TOPGLOV2024-12-26
TOPGLOV2024-12-26
TOPGLOV2024-12-24
TOPGLOV2024-12-24
TOPGLOV2024-12-23
TOPGLOV2024-12-23
TOPGLOV2024-12-23
TOPGLOV2024-12-23
TOPGLOV2024-12-23
TOPGLOV2024-12-23
TOPGLOV
2024-12-23
TOPGLOV2024-12-23
TOPGLOV2024-12-23
TOPGLOV2024-12-23
TOPGLOV2024-12-20
HARTA2024-12-20
TOPGLOV2024-12-20
TOPGLOV2024-12-19
HARTA2024-12-19
HARTA2024-12-19
SUPERMX2024-12-19
SUPERMX2024-12-19
SUPERMX2024-12-19
SUPERMX2024-12-19
SUPERMX2024-12-19
TOPGLOV2024-12-18
SUPERMX2024-12-17
HARTA2024-12-17
HARTA2024-12-16
SUPERMX2024-12-16
SUPERMX2024-12-16
TOPGLOVMore articles on gloveharicut
TOPGLOV 4QFY22 Briefing slides - good time to bottom fishing?
Created by gloveharicut | Sep 20, 2022
CIMB: BUY DKSH. Target RM5.30. Beat expectations on strong margins
Created by gloveharicut | Aug 30, 2021
HARTA 2021 Q4 Briefing Slide - Differentiate from others by growing a truly sustainable business
Created by gloveharicut | May 04, 2021
GLOVEs to stay in limelight amid resurgence of Covid-19 cases
Created by gloveharicut | Apr 19, 2021
Discussions
7 people like this. Showing 3 of 3 comments
u should reconsider switching to Thailand Sri Trang Gloves, half the valuation, no risk of windfall tax, an undiscovered glove gem
2020-08-21 13:47
Bloomberg - Indian tech group withdraws from vaccine race saying not worth it (12:58 p.m. HK) A group of Indian Institute of Technology alumni and academics has withdrawn from the vaccine development race. It’s neither viable nor safe to do such research at a hectic pace and with inadequate data, IIT Alumni Council said in an Aug. 24 statement.
Only 2% of Covid-19 patients need critical care and they can most likely be treated with antibody-based biologics, Daljit Singh, an IIT alumnus and former president at Fortis Healthcare said in the statement.
A vaccine, on the other hand, will need to protect nearly the entire population in order to be effective. “Chasing 2% of the population with a 98% sure cure has a far better probability of success than chasing 98% of the population with a 2% surety of safety and efficacy,” he said.
2020-08-25 15:17
Post a Comment
Featured Posts
Introducing MY's First IPO Fund for Sophisticated Investors!
New Update. Discover investment communities that resonate with your ideas
M & A Value Partners IPO Equity Fund has been launched - Targeted 13% Return p.a
Latest Videos
Apps
Top Articles
2
3
Koon Yew Yin's Blog
5
THE INVESTMENT APPROACH OF CALVIN TAN
SUPERMAX VERSUS TOPGLOVE, KOSSAN & HARTA, Compare & Contrast, By Calvin Tan
6
7
8
#
Stock
Score
Daily Stocks
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Featured Advertisers / Partners
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
devadra
Any news
2020-08-20 21:21